MARKET

XCUR

XCUR

Exicure Inc
NASDAQ
1.080
+0.020
+1.89%
After Hours: 1.100 +0.02 +1.85% 18:33 11/13 EST
OPEN
1.010
PREV CLOSE
1.060
HIGH
1.080
LOW
1.010
VOLUME
7.91K
TURNOVER
--
52 WEEK HIGH
9.48
52 WEEK LOW
0.7770
MARKET CAP
7.07M
P/E (TTM)
-0.8290
1D
5D
1M
3M
1Y
5Y
1D
Exicure Inks $4.8M Asset Deal to Strengthen Balance Sheet
Benzinga · 3d ago
Exicure Agrees to Sell GPC-100 Program Assets
TipRanks · 4d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 4d ago
Exicure agrees to sell GPC-100 assets for $4.8M; shares rally over 21%
Seeking Alpha · 4d ago
Exicure agrees to sell GPC-100 program assets for $4.8M
TipRanks · 4d ago
Exicure Agrees To Sell Its GPC-100 Program Assets To GPCRT For ~$4.8M In Cash
Benzinga · 4d ago
Weekly Report: what happened at XCUR last week (1102-1106)?
Weekly Report · 5d ago
Weekly Report: what happened at XCUR last week (1026-1030)?
Weekly Report · 11/02 09:00
More
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Webull offers Exicure Inc stock information, including NASDAQ: XCUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XCUR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XCUR stock methods without spending real money on the virtual paper trading platform.